New shingles vaccine trial aims to protect older adults
Disease control
Not yet recruiting
This study tests a new shingles vaccine (CVI-VZV-001) in healthy adults aged 50 and older. Researchers will compare it to an existing vaccine to see how well it boosts the immune system and check for side effects. The goal is to find the best dose to prevent shingles.
Phase: PHASE2 • Sponsor: CHA Vaccine Institute Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC